{'52WeekChange': -0.1574074,
 'SandP52WeekChange': 0.0644362,
 'address1': '100 Princeton South',
 'address2': 'Suite 300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.74,
 'askSize': 3000,
 'averageDailyVolume10Day': 892812,
 'averageVolume': 1232134,
 'averageVolume10days': 892812,
 'beta': 1.35014,
 'beta3Year': None,
 'bid': 2.73,
 'bidSize': 2900,
 'bookValue': 0.325,
 'category': None,
 'circulatingSupply': None,
 'city': 'Ewing',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.8,
 'dayLow': 2.71,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 63.626,
 'enterpriseToRevenue': 3.357,
 'enterpriseValue': 448693888,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 2.8022857,
 'fiftyTwoWeekHigh': 5.13,
 'fiftyTwoWeekLow': 1.6,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 152861918,
 'forwardEps': 0.24,
 'forwardPE': 11.375,
 'fromCurrency': None,
 'fullTimeEmployees': 178,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.07451,
 'heldPercentInstitutions': 0.41629001,
 'industry': 'Medical Instruments & Supplies',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 917568000,
 'lastSplitFactor': '1:5',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/antarespharma.com',
 'longBusinessSummary': 'Antares Pharma, Inc. focuses on developing and '
                        'commercializing self-administered parenteral '
                        'pharmaceutical products and technologies in the '
                        'United States, Europe, and internationally. The '
                        "company's injection products include OTREXUP that "
                        'comprises of pre-filled methotrexate syringe and '
                        'VIBEX self-injection system to enable rheumatoid '
                        'arthritis (RA) and psoriasis patients to self-inject '
                        'methotrexate at home; XYOSTED for the treatment of '
                        'testosterone deficiency in adult males; Sumatriptan '
                        'Injection USP for the acute treatment of migraine and '
                        'cluster headache in adults. Its injection products '
                        'also comprise Epinephrine Injection USP for treating '
                        'Anaphylaxis; Makena auto injectors to reduce the risk '
                        'of preterm birth in women pregnant with a single '
                        'baby; ZOMAJET and Twin-Jector EZ II Needle-free '
                        'Injectors to administer human growth hormone for '
                        'patients with growth retardation. In addition, the '
                        'company develops disposable pen injectors for '
                        'diabetes and osteoporosis; and QuickShot auto '
                        'injectors. It has strategic alliances with Teva '
                        'Pharmaceutical Industries, Ltd., AMAG '
                        'Pharmaceuticals, Inc., Idorsia Pharmaceuticals Ltd, '
                        'and Pfizer Inc. The company was founded in 1978 and '
                        'is headquartered in Ewing, New Jersey.',
 'longName': 'Antares Pharma, Inc.',
 'market': 'us_market',
 'marketCap': 451978816,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_764293',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 1156000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.78,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 1.78,
 'phone': '609 359 3020',
 'previousClose': 2.81,
 'priceHint': 4,
 'priceToBook': 8.400001,
 'priceToSalesTrailing12Months': 3.381632,
 'profitMargins': 0.00865,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.8,
 'regularMarketDayLow': 2.71,
 'regularMarketOpen': 2.78,
 'regularMarketPreviousClose': 2.81,
 'regularMarketPrice': 2.78,
 'regularMarketVolume': 648389,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 165560000,
 'sharesPercentSharesOut': 0.0322,
 'sharesShort': 5336829,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4690243,
 'shortName': 'Antares Pharma, Inc.',
 'shortPercentOfFloat': 0.0328,
 'shortRatio': 4.32,
 'startDate': None,
 'state': 'NJ',
 'strikePrice': None,
 'symbol': 'ATRS',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 0.007,
 'trailingPE': 390,
 'twoHundredDayAverage': 3.0229497,
 'volume': 648389,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.antarespharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '08628'}